Form 4: Krystal Biotech Director Catherine Mazzacco Granted 5,000 Stock Options

Krystal Biotech, Inc. Director Catherine Mazzacco was granted 5,000 stock options with an exercise price of $137.46, vesting monthly over one year.

Summary

• Catherine Mazzacco, a Director of Krystal Biotech, Inc. (KRYS), was granted 5,000 stock options.
• The options have an exercise price of $137.46 per share.
• The grant date for these options was June 30, 2025.
• The options will vest in equal monthly tranches over a one-year period, starting from the grant date.
• The expiration date for these options is June 30, 2035.
• Following this transaction, Catherine Mazzacco beneficially owns 5,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive sign as it aligns interests and incentivizes long-term performance, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of stock options to a director aligns management incentives with shareholder interests.
• The options have a long expiration date of June 30, 2035, providing a significant window for potential value realization.

Risks

• The value of the stock options is dependent on the future performance of Krystal Biotech's common stock; if the stock price does not exceed the exercise price of $137.46, the options may expire worthless.

Future Outlook

The grant of stock options indicates a long-term incentive for the director, aligning their financial interests with the future growth and stock performance of Krystal Biotech over the next decade.

Management Comments

• No direct management comments or quotes are typically found in a Form 4 filing, which is a transactional report.

Industry Context

The grant of stock options is a standard practice in the biotechnology and pharmaceutical industries to incentivize and retain key personnel, including directors, by linking their compensation to the company's long-term stock performance and success in drug development and commercialization.

Comparison to Industry Standards

• Granting stock options to directors is a common compensation practice across the biotechnology sector, similar to companies like Moderna (MRNA) or BioNTech (BNTX), where equity-based incentives are used to align leadership interests with shareholder value creation.
• The vesting schedule of equal monthly tranches over one year is a typical short-to-medium term vesting period for such grants, though longer vesting periods (e.g., 3-4 years) are also common for executive equity awards.
• The exercise price being set at the market price on the grant date is standard for incentive stock options, ensuring that the options gain value only if the company's stock price appreciates.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholder value creation, potentially leading to better long-term performance.

Next Steps

• The options will vest in equal monthly tranches over a one-year period following the June 30, 2025 grant date.
• Catherine Mazzacco may choose to exercise these options at any time between their vesting date and the expiration date of June 30, 2035, provided the stock price is above the exercise price.

Key Dates

Keywords

Krystal Biotech, KRYS, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Catherine Mazzacco